排序方式: 共有31条查询结果,搜索用时 15 毫秒
1.
Chandra Kirana Graham Peter Jones Ian Roland Record Graeme Howie McIntosh 《Journal of natural medicines》2007,61(2):131-137
Extract of Boesenbergia pandurata (Kaempferia pandurata) (Zingiberaceae) has been used as a replacement for K. rotunda, the main ingredient of a popular traditional tonic called “jamu” especially for women in Indonesia. From our previous study,
ethanolic extract of B. pandurata showed strong inhibitory effects on the growth of cancer cells, similar to ethanolic extract of Curcuma longa. C. longa and its bioactive compound, curcumin, have shown potential anticancer activity in in vitro and in vivo studies and have undergone
clinical trials. Panduratin A, a chalcone derivative isolated from B. pandurata, was found to inhibit the growth of MCF-7 human breast cancer and HT-29 human colon adenocarcinoma cells with an IC50 of 3.75 and 6.56 μg/ml, respectively. Panduratin A arrested cancer cells labelled with Annexin-V and propidium iodide in
the G0/G1 phase and induced apoptosis in a dose-dependent manner. In an animal model study, male Sprague–Dawley rats were
fed with AIN diet containing ethanolic extracts prepared from the equivalent of 4% by weight of dried rhizomes of B. pandurata and C. longa. Aberrant crypt foci (ACFs) were induced by two subcutaneous doses (15 mg/kg body weight) of azoxymethane (AOM) 1 week apart.
The rats were killed 10 weeks later, and the ACFs were assessed in the colon. At the dose given to rats, it appeared that
the extracts were not toxic. Total ACFs were slightly reduced by B. pandurata extract compared to control group but not significantly different. Extract of B. pandurata may have a protective effect against colon cancer but additional studies using different models, such as a breast cancer
model, need to be carried out. 相似文献
2.
The anticancer properties of zerumbone (2,6,9 humulatriene-8-one, a sesquiterpenoid) from Zingiber aromaticum were compared with those of curcumin from Curcuma longa in an in vitro MTT tetrazolium salt assay using HT-29, CaCo-2, and MCF-7 cancer cells and in an azoxymethane (AOM)-induced animal model of colon cancer using aberrant crypt foci (ACFs) as a preneoplastic marker. The IC50 of zerumbone was approximately 10 mM and that of curcumin was 25 mM. Cell cycle arrest in HT-29 cells was observed at G0/G1 for 10 and 12.5 mM and G2/M for 25 mM after 24 h at concentrations of 10-25 mM of zerumbone, and a concentration-dependent increase in apoptosis (2-6% of viable cells) was observed after 48 h using the same concentration range. Male Sprague-Dawley rats were fed extracts in an AIN diet prepared from the equivalent of 4% by weight of dried rhizomes of Z. aromaticum and C. longa. ACFs were induced by two doses (15 mg/kg body weight) subcutaneously of AOM 1 wk apart, the rats were killed 10 wk later, and the ACFs were assessed in the colon. Total ACFs were significantly reduced by Z. aromaticum extract (down 21%, P < 0.05) relative to control, the effect being most evident with large ACFs (>3 aberrant crypts per focus). Similar reductions were observed with 4% C. longa extract in the diet (down 24%, P < 0.01) and with 2,000 ppm curcumin, the effect being particularly evident with large ACFs. The concentration of zerumbone in the Z. aromaticum extract diet was assayed at 300 ppm and of curcumin in the C. longa extract diet was also 300 ppm, i.e., the extract of C. longa was as effective at one-seventh the concentration of curcumin as the positive control. Zerumbone is effective as an anticancer agent, possibly by its apoptosis-inducing and antiproliferative influences. This latter possibility is currently being investigated. 相似文献
3.
Discordant frequencies of tissue‐resident and circulating CD180‐negative B cells in chronic rhinosinusitis 下载免费PDF全文
4.
5.
Scimitar syndrome is a rare and complex congenital anomaly, which is characterized by the image of a Turkish sword on the chest X-ray. Very few cases in adults are reported in the literature. The long-term results of scimitar syndrome after surgical correction remain disappointing. We report an adult patient with scimitar syndrome undergoing surgery at our center. 相似文献
6.
Apostolos Apostolidis Paraskevi-Sofia Kirana Gretchen Chiu Carol Link Marina Tsiouprou Dimitrios Hatzichristou 《European urology》2009
Background
Few comparisons have been made of health care seeking behaviour for lower urinary tract symptoms (LUTS) between men and women, as well as trends across age groups.Objective
To investigate the bother from LUTS and effect on health care seeking in both men and women of different age groups and in comparison between the two genders.Design, setting, and participants
A representative cross section of each of 13 clinics of a general academic hospital, with equal numbers of subjects recruited in each of six design cells that were defined by age (18–40, 41–60, 61–80 yr) and gender.Intervention
A 2-h in-person interview, conducted by a trained psychologist/interviewer in a clinic office.Measurements
Severity of LUTS was measured by the International Prostate Symptom Score (IPSS). Treatment seeking was measured by a single item. A bother question was modified to assess overall bother. Impact on quality of life (QoL) was measured by the IPSS QoL question.Results and limitations
The final study sample comprised 415 patients. More women than men reported the presence of LUTS (85.5% vs 75.2%; p = 0.01). LUTS were more bothersome in women (25.4% of women vs 17.6% of men with bother “some” or “a lot”; p = 0.02). Severity of LUTS increased with age in both genders (men: p < 0.001; women: p = 0.03). Bother from LUTS increased as severity of symptoms increased in both genders (p < 0.001) but was associated with age only in men (p < 0.001). QoL showed similar results as bother. Although men and women had equal prevalence of treatment seeking (27.9% vs 23.7%; p = 0.40), men, but not women, were more likely to seek treatment as age (p < 0.01) and severity of LUTS (p < 0.001) increased. In multivariate logistic regressions, only bother from LUTS was associated with treatment seeking in women, compared with bother, age, and the presence of voiding symptoms in men.Conclusions
In our hospital-based sample, differences in LUTS frequency, bother, and health care seeking profiles between men and women suggest a different perception and response to LUTS between the two genders. 相似文献7.
Papaharitou S Nakopoulou E Kirana P Giaglis G Moraitou M Hatzichristou D 《Archives of gerontology and geriatrics》2008,46(2):191-201
The present study aimed to investigate factors associated with sexual interest and behaviors in married older adults. The study recruited older adults from the Open Protection Centers for Elderly. A 30-items questionnaire addressing sexuality, emotional and physical intimacy, demographics, and background data was constructed. Dichotomous responses were used for intimacy and sexuality items. Data were analyzed using Chi-square tests, Pearson's correlation coefficient and Independent samples t-test. The sample consisted of 454 married participants (age range: 60-90, mean: 69.0+/-6.5). More than 50% reported having sexual desire and intercourse's average frequency of 4/month. Increasing age and marriage's years related significantly to decreased frequency of sexual intercourse (p<0.001). Participants married out of love reported higher frequency of intercourse p.a. compared with those in arranged marriages (p=0.031). Gender, age, income, married out of love and being still in love with the partner were all significantly associated with sexual interest and behaviors (p<0.05). This study demonstrates that older adults remain sexually active and a range of personal, socio-economic and interpersonal factors are associated with sexual interest. Therefore, sexual expression should be a well-informed individual's choice and not the result of societal myths or health professionals' misconceptions. 相似文献
8.
9.
Jaoko W Nakwagala FN Anzala O Manyonyi GO Birungi J Nanvubya A Bashir F Bhatt K Ogutu H Wakasiaka S Matu L Waruingi W Odada J Oyaro M Indangasi J Ndinya-Achola J Konde C Mugisha E Fast P Schmidt C Gilmour J Tarragona T Smith C Barin B Dally L Johnson B Muluubya A Nielsen L Hayes P Boaz M Hughes P Hanke T McMichael A Bwayo J Kaleebu P 《Vaccine》2008,26(22):2788-2795
The safety and immunogenicity of plasmid pTHr DNA, modified vaccinia virus Ankara (MVA) human immunodeficiency virus type 1 (HIV-1) vaccine candidates were evaluated in four Phase I clinical trials in Kenya and Uganda. Both vaccines, expressing HIV-1 subtype A gag p24/p17 and a string of CD8 T-cell epitopes (HIVA), were generally safe and well-tolerated. At the dosage levels and intervals tested, the percentage of vaccine recipients with HIV-1-specific cell-mediated immune responses, assessed by a validated ex vivo interferon gamma (IFN-γ) ELISPOT assay and Cytokine Flow Cytometry (CFC), did not significantly differ from placebo recipients. These trials demonstrated the feasibility of conducting high-quality Phase 1 trials in Africa. 相似文献
10.
Anita H. Clayton Irwin Goldstein Noel N. Kim Stanley E. Althof Stephanie S. Faubion Brooke M. Faught Sharon J. Parish James A. Simon Linda Vignozzi Kristin Christiansen Susan R. Davis Murray A. Freedman Sheryl A. Kingsberg Paraskevi-Sofia Kirana Lisa Larkin Marita McCabe Richard Sadovsky 《Mayo Clinic proceedings. Mayo Clinic》2018,93(4):467-487
The International Society for the Study of Women's Sexual Health process of care (POC) for management of hypoactive sexual desire disorder (HSDD) algorithm was developed to provide evidence-based guidelines for diagnosis and treatment of HSDD in women by health care professionals. Affecting 10% of adult females, HSDD is associated with negative emotional and psychological states and medical conditions including depression. The algorithm was developed using a modified Delphi method to reach consensus among the 17 international panelists representing multiple disciplines. The POC starts with the health care professional asking about sexual concerns, focusing on issues related to low sexual desire/interest. Diagnosis includes distinguishing between generalized acquired HSDD and other forms of low sexual interest. Biopsychosocial assessment of potentially modifiable factors facilitates initiation of treatment with education, modification of potentially modifiable factors, and, if needed, additional therapeutic intervention: sex therapy, central nervous system agents, and hormonal therapy, guided in part by menopausal status. Sex therapy includes behavior therapy, cognitive behavior therapy, and mindfulness. The only central nervous system agent currently approved by the US Food and Drug Administration (FDA) for HSDD is flibanserin in premenopausal women; use of flibanserin in postmenopausal women with HSDD is supported by data but is not FDA approved. Hormonal therapy includes off-label use of testosterone in postmenopausal women with HSDD, which is supported by data but not FDA approved. The POC incorporates monitoring the progress of therapy. In conclusion, the International Society for the Study of Women's Sexual Health POC for the management of women with HSDD provides a rational, evidence-based guideline for health care professionals to manage patients with appropriate assessments and individualized treatments. 相似文献